Intriguingly, at equivalent dosages, Msol demonstrated a more substantial improvement in reducing IL-1β and COX-2 expressions compared to MS, highlighting its superior therapeutic efficacy. The gene discussed is IL1B; the disease is myeloid sarcoma.